Raleigh Capital Management’s GSK GSK Stock Holding History

Raleigh Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$197K	Sell	3,570 -26,529	-88%	-$1.44M	0.07%	201
2025 Q4	$1.48M	Sell	30,099 -5,240	-15%	-$244K	0.54%	57
2025 Q3	$1.53M	Buy	35,339 +351	+1%	+$13.7K	0.58%	59
2025 Q2	$1.34M	Buy	+34,988	New	+$1.34M	0.56%	56
2025 Q1	–	Sell	-48	Closed	-$1.62K	–	760
2024 Q4	$1.62K	Hold	48	–	–	﹤0.01%	854
2024 Q3	$1.96K	Hold	48	–	–	﹤0.01%	819
2024 Q2	$1.85K	Hold	48	–	–	﹤0.01%	792
2024 Q1	$2.06K	Sell	48 -16	-25%	-$660	﹤0.01%	763
2023 Q4	$2.35K	Hold	64	–	–	﹤0.01%	849
2023 Q3	$2.3K	Buy	64 +16	+33%	+$568	﹤0.01%	765
2023 Q2	$1.71K	Buy	+48	New	+$1.72K	﹤0.01%	742
2022 Q4	–	Sell	-174	Closed	-$5K	–	821
2022 Q3	$5K	Sell	174 -112	-39%	-$4.25K	﹤0.01%	482
2022 Q2	$16K	Hold	286	–	–	0.01%	307
2022 Q1	$16K	Sell	286 -8	-3%	-$435	0.01%	311
2021 Q4	$16K	Buy	+294	New	+$15.3K	0.02%	173

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Raleigh Capital Management's GSK Position: Q1 2026 in Review

Raleigh Capital Management reduced its GSK (GSK) stake by 88% in Q1 2026, selling an estimated $1.44M and leaving 3,570 shares worth $197K. The position accounts for 0.07% of the portfolio, ranked #201.

Raleigh Capital Management first reported a position in GSK in Q4 2021 and has held it in 15 quarters since. The position peaked at $1.53M in Q3 2025. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Raleigh Capital Management held 3,570 shares of GSK worth $197K as of Q1 2026.
Raleigh Capital Management sold 26,529 GSK shares in Q1 2026, an estimated $1.44M.
GSK made up 0.07% of Raleigh Capital Management's portfolio in Q1 2026, its #201 holding.
Raleigh Capital Management first reported a position in GSK in Q4 2021 and has held it in 15 quarters since.
Raleigh Capital Management's GSK position peaked at $1.53M in Q3 2025.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Raleigh Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.